Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Jobin K. John"'
Autor:
Keiran S.M. Smalley, Hussein Tawbi, Darrin Stuart, Geoffrey T. Gibney, Sarah Sloot, Friedegund Meier, John M. Kirkwood, Uma N. Rao, Alejandro Villagra, Elena B. Pasquale, Jane L. Messina, Vernon K. Sondak, Keith T. Flaherty, Hensin Tsao, Jobin K. John, Inna V. Fedorenko, John M. Koomen, Bin Fang, Meghna Das Thakur, Kim H.T. Paraiso
Supplemental Figure 1. Characterization of the resistant cell lines. Supplemental Figure 2. Quantification of the cell invasion from figure 1D. Supplemental Figure 3. Model showing ligand dependent and independent ephrin signaling. Supplemental Figur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dce9c47489ab84a6f2137134ee8395f
https://doi.org/10.1158/2159-8290.22530725
https://doi.org/10.1158/2159-8290.22530725
Autor:
Keiran S.M. Smalley, John M. Koomen, Amod A. Sarnaik, Jobin K. John, Vernon K. Sondak, Jeffrey S. Weber, Roger S. Lo, Antoni Ribas, Yun Xiang, Y. Ann Chen, Vito W. Rebecca, Elizabeth Wood, H. Eirik Haarberg, Kim H.T. Paraiso
Purpose: The clinical use of BRAF inhibitors is being hampered by the acquisition of drug resistance. This study shows the potential therapeutic use of the HSP90 inhibitor (XL888) in six different models of vemurafenib resistance.Experimental Design:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0facfb45f36b22df26d5fa1ddc7e3bc2
https://doi.org/10.1158/1078-0432.c.6520034
https://doi.org/10.1158/1078-0432.c.6520034
Autor:
Keiran S.M. Smalley, John M. Koomen, Amod A. Sarnaik, Jobin K. John, Vernon K. Sondak, Jeffrey S. Weber, Roger S. Lo, Antoni Ribas, Yun Xiang, Y. Ann Chen, Vito W. Rebecca, Elizabeth Wood, H. Eirik Haarberg, Kim H.T. Paraiso
CCR Translation for This Article from The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e357b1f2567555476ae651e8528408f
https://doi.org/10.1158/1078-0432.22443995.v1
https://doi.org/10.1158/1078-0432.22443995.v1
Autor:
Keiran S.M. Smalley, John M. Koomen, Amod A. Sarnaik, Jobin K. John, Vernon K. Sondak, Jeffrey S. Weber, Roger S. Lo, Antoni Ribas, Yun Xiang, Y. Ann Chen, Vito W. Rebecca, Elizabeth Wood, H. Eirik Haarberg, Kim H.T. Paraiso
PDF file - 1.0MB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b232ae8dc464c198462149e1a943a59f
https://doi.org/10.1158/1078-0432.22443992.v1
https://doi.org/10.1158/1078-0432.22443992.v1
Autor:
Eric Meggers, Bin Fang, Jobin K. John, Clemens Krepler, Vito W. Rebecca, Victoria Izumi, Nicholas Pagano, Jane L. Messina, John M. Koomen, Keiran S.M. Smalley, Kim H. T. Paraiso, Ethan V. Abel, Meenhard Herlyn, Liliana Cantini, Rahel Mathew
Publikováno v:
The Journal of investigative dermatology
This study addresses the role of glycogen synthase kinase (GSK)-3β signaling in the tumorigenic behavior of melanoma. Immunohistochemical staining revealed GSK3β to be focally expressed in the invasive portions of 12 and 33% of primary and metastat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6b088f18465b7b4e9e36cb5d0cd4456
Autor:
Keiran S.M. Smalley, Jobin K. John
Publikováno v:
Expert Review of Anticancer Therapy. 11:711-714
Eruptive melanocytic naevi (EMN) are melanocytic proliferations developing rapidly on previously unaffected skin in association with various clinical scenarios, most commonly systemic immunosuppression. However, the exact mechanism leading to develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb9e0896026a13607f5dd55c53d2735e
https://doi.org/10.1586/era.11.30
https://doi.org/10.1586/era.11.30
Autor:
Keith T. Flaherty, Vernon K. Sondak, Keiran S.M. Smalley, Friedegund Meier, Jane L. Messina, Elena B. Pasquale, Sarah Sloot, Geoffrey T. Gibney, Jobin K. John, John M. Koomen, John M. Kirkwood, Hensin Tsao, Meghna Das Thakur, Hussein Tawbi, Bin Fang, Alejandro Villagra, Kim H. T. Paraiso, Uma N. M. Rao, Darrin Stuart, Inna V. Fedorenko
Publikováno v:
Cancer discovery. 5(3)
Many patients with BRAF inhibitor resistance can develop disease at new sites, suggesting that drug-induced selection pressure drives metastasis. Here, we used mass spectrometry–based phosphoproteomic screening to uncover ligand-independent EPHA2 s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c7b2d9689f88ef377142012110ef104
https://pubmed.ncbi.nlm.nih.gov/25542447
https://pubmed.ncbi.nlm.nih.gov/25542447
Autor:
Y. Ann Chen, Kim H. T. Paraiso, Amod A. Sarnaik, Jobin K. John, Antoni Ribas, Jeffrey S. Weber, Roger S. Lo, John M. Koomen, Keiran S.M. Smalley, Vernon K. Sondak, Yun Xiang, Vito W. Rebecca, Elizabeth R. Wood, H. Eirik Haarberg
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 18(9)
Purpose: The clinical use of BRAF inhibitors is being hampered by the acquisition of drug resistance. This study shows the potential therapeutic use of the HSP90 inhibitor (XL888) in six different models of vemurafenib resistance. Experimental Design
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b32c9d2b7c3dc9f6713f400503b6d3e5
https://pubmed.ncbi.nlm.nih.gov/22442059
https://pubmed.ncbi.nlm.nih.gov/22442059
Publikováno v:
Biotargets of Cancer in Current Clinical Practice ISBN: 9781617796142
Skin cancers are the most prevalent of all malignancies with 50% of all Americans reaching the age of 65 expected to develop one form of skin cancer in their lifetimes. The two most common forms of skin cancer, basal cell carcinoma and squamous cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1805b1fa6186f4b55f726aa7ef10ffc
https://doi.org/10.1007/978-1-61779-615-9_17
https://doi.org/10.1007/978-1-61779-615-9_17
Autor:
Keith T. Flaherty, Kerian S. M. Smalley, Inna V. Fedorenko, Dale Han, Jobin K. John, Friedegund Meier, Bin Fang, Kim H. T. Paraiso, Jennifer A. Wargo, John M. Koomen
Publikováno v:
Cancer Research. 73:5237-5237
Although initially striking, the therapeutic efficacy of BRAF inhibition is eventually undermined by adaptive cellular signaling that leads to progressive disease. To date, several mechanisms of BRAF inhibitor resistance have been reported focusing p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::031e9161bd37b1914dd9c9090c5a6648
https://doi.org/10.1158/1538-7445.am2013-5237
https://doi.org/10.1158/1538-7445.am2013-5237